首页> 外文期刊>Molecular cancer therapeutics >Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma.
【24h】

Recombinant adeno-associated virus encoding Epstein-Barr virus latent membrane proteins fused with heat shock protein as a potential vaccine for nasopharyngeal carcinoma.

机译:编码与热激蛋白融合的爱泼斯坦-巴尔病毒潜伏膜蛋白的重组腺相关病毒,作为鼻咽癌的潜在疫苗。

获取原文
获取原文并翻译 | 示例
       

摘要

Nasopharyngeal carcinoma (NPC) is a common cancer in Southern China and EBV is the most important pathogenesis. In this study, we explore the potential that a recombinant adeno-associated virus (rAAV) carrying a fusing gene containing heat shock protein as an adjuvant, EBV latent membrane proteins (LMP1 and LMP2) CTL epitope DNA as a vaccine prevents NPC. The tumor vaccine was devised by constructing a chimeric gene which contained EBV LMPs CTL epitope DNA fused with the heat shock protein gene as a tumor vaccine delivered via rAAV. Our results show that this vaccine can eliminate tumors in syngeneic animals and induce CTL activity in vitro. Taken together, the data suggest that this chimeric gene delivered by rAAV has potential as a NPC vaccine for prevention and therapy.
机译:鼻咽癌(NPC)是华南地区的常见癌症,而EBV是最重要的发病机制。在这项研究中,我们探讨了携带带有热休克蛋白作为佐剂,EBV潜伏膜蛋白(LMP1和LMP2)CTL表位DNA作为疫苗的融合基因的重组腺相关病毒(rAAV)预防NPC的潜力。通过构建包含EBV LMPs CTL表位DNA与热休克蛋白基因融合的嵌合基因作为通过rAAV递送的肿瘤疫苗,来设计肿瘤疫苗。我们的结果表明,这种疫苗可以消除同类动物的肿瘤,并在体外诱导CTL活性。总体而言,数据表明,rAAV传递的这种嵌合基因具有作为预防和治疗NPC疫苗的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号